The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome
Official Title: Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome
Study ID: NCT01541280
Brief Summary: Patients included in the study with high risk acute myeloid leukemia or myelodysplastic syndrome as defined will receive an allogeneic transplantation conditioned by either myeloablative or reduced regimen. Following allogeneic transplantation, patients will receive a maintenance regimen combining chemotherapy with azacitidine (aza) and immunotherapy with donor lymphocyte infusion.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University Hospital of Nantes, Nantes, , France
Name: Milpied Noel, Professor
Affiliation: CHU Bordeaux
Role: PRINCIPAL_INVESTIGATOR
Name: Guillaume Thierry, Doctor
Affiliation: Nantes University Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Yakoub-Agha Ibrahim, Professor
Affiliation: CHU Lille
Role: PRINCIPAL_INVESTIGATOR
Name: Huynh Anne, Doctor
Affiliation: CHU Toulouse
Role: PRINCIPAL_INVESTIGATOR
Name: Blaise Didier, Professor
Affiliation: Institut-Paoli Calmettes Marseille
Role: PRINCIPAL_INVESTIGATOR
Name: Mohamad Mothy, Professor
Affiliation: Hôpital Saint Antoine
Role: PRINCIPAL_INVESTIGATOR